Breast cancer: Are estrogen metabolites carcinogenic?

Climacteric

Volumn 10, Issue SUPPL. 2, 2007, Pages 62-65

  Mueck, A O ^a,b   Seeger, H ^a  

^a University Women's Hospital of Tuebingen   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Breast cancer; Estrogen; Metabolites

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 METHOXYESTRADIOL; 4 HYDROXYESTROGEN; DRUG METABOLITE; ESTRADIOL; ESTROGEN; TOXIN; UNCLASSIFIED DRUG;

BREAST CANCER; CARCINOGENICITY; CIGARETTE SMOKING; CONFERENCE PAPER; DEFENSE MECHANISM; DRUG METABOLISM; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADMINISTRATION, CUTANEOUS; ANIMALS; BREAST NEOPLASMS; CARCINOGENS; ESTRADIOL; ESTRIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; STEROID 16-ALPHA-HYDROXYLASE;

EID: 34548833321     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701598811     Document Type: Conference Paper

References (19)

1. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;354:270-82
2. Liehr JG, Roy D. Free radical generation by redox cycling of estrogens. Free Radic Biol Med 1990;8:415-23
3. Chen Y, Liu X, Pisha E, et al. A metabolite of equine estrogens, 4-hydroxyequilenin, induces DNA damage and apoptosis in breast cancer cell lines. Chem Res Toxicol 2000;13:342-50
4. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
5. Osborne MP, Bradlow HL, Wong GY, Telang NT. Upregulation of estradiol 16α-hydroxylation in human breast tissue: potential biomarker of breast cancer risk. J Natl Cancer Inst 1993;85:1917-20
6. Bradlow HL, Hershcopf RJ, Martucci CP, Fishman J. Estradiol 16α-hydroxylation in the mouse correlates with tumor incidence and presence of murine mammary tumor virus: a possible model for the hormonal etiology of breast cancer in humans. Proc Natl Acad Sci USA 1985;82:6295-9
7. Mueck AO, Zimmermann B, Diesing D, Seeger H, Huober J. Impact of estradiol metabolites on breast cancer risk and factors influencing estradiol metabolism - case control study. J Br Menopause Soc 2003;9(Suppl 2):31
8. Kabat GC, O'Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology 2006;17:80-8
9. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicin binding site. J Med Chem 1985;38:2041-9
10. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogenmetabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994;368:237-9
11. Seeger H, Huober J, Wallwiener D, Mueck AO. Effect of tamoxifen and 2-methoxyestradiol alone and in combination on human breast cancer cell proliferation. J Steroid Biochem Mol Biol 2003;84:255-7
12. Mueck AO, Seeger H, Huober J. Chemotherapy of breast cancer - additive anticancerogenic effect by 2-methoxyestradiol? Life Sci 2004;75:1205-10
13. Service RF. New role for estrogen in cancer? Science 1998;279:1631-3
14. Mueck AO, Seeger H. Smoking, estradiol metabolism and hormone replacement therapy. Drug Res 2003;53:1-11
15. Berstein LM, Tsyrlina EV, Kolesnik OS, Gamajunova VB, Adlercreutz H. Catecholestrogens excretion in smoking and non-smoking postmenopausal women receiving estrogen replacement therapy. J Steroid Biochem Mol Biol 2000;72:143-7
16. Lippert TH, Seeger H, Mueck AO. Estradiol metabolism during oral and transdermal estradiol replacement therapy in the postmenopause. Horm Metab Res 1998;30:598-600
17. Seeger H, Mueck AO, Lippert TH. Effect of norethisterone acetate on estradiol metabolism in postmenopausal women. Horm Metab Res 2000;32:436-9
18. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354-60
19. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: result from the E3N cohort study. Breast Cancer Res Treat 2007 Feb 27;[Epub ahead of print]